Hepatocellular Cancer Clinical Trial
Official title:
Phase I Open-Label, Dose-Finding Study of BAY 43-9006 (Sorafenib) in High-risk Hepatocellular Cancer Patients After Liver Transplantation
Verified date | August 2015 |
Source | Columbia University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
This Phase I study of sorafenib in high risk hepatocellular cancer patients after liver transplantation will study 24 subjects for about 5 years. Each subject will receive sorafenib for 6 months. Safety and effectiveness on the post transplant, high risk HCC patients will be studied.
Status | Completed |
Enrollment | 14 |
Est. completion date | May 2015 |
Est. primary completion date | May 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Age =18 years old - ECOG Performance Status 0-2 - Post liver transplant and have explants with histologically confirmed hepatocellular carcinoma. - No evidence of HCC disease at study entry by imaging - Eligible to start 4 weeks post transplant (29 days post transplant) as long as they are on stable doses of immunosuppressants. - "High risk" for recurrence after transplantation - Received prior surgical resection, chemoembolization or other local therapy prior to transplant. - Have Child-Pugh Class A or compensated Child-Pugh Class B liver dysfunction at the start of therapy - Have adequate bone marrow, liver and renal function as assessed by the following: - Hemoglobin = 8.0 g/dl - Absolute neutrophil count (ANC) = 1,500/mm3 - Platelet count = 75,000/mm3 - Total bilirubin = 1.5 times ULN - ALT and AST = 5 x ULN - Creatinine = 1.5 times ULN - Albumin = 2.5 mg/dl - Women of childbearing potential must have a negative serum pregnancy test performed within 14 days prior to the start of treatment - Women of childbearing potential and men must agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation. Men should use adequate birth control for at least three months after the last administration of sorafenib. - Exhibit the ability to understand and willingness to sign a written informed consent regarding the study and alternative treatments. - INR < 1.5 or a PT/PTT within normal limits. Exclusion Criteria: - Cardiac disease: Congestive heart failure > class II NYHA. - Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy. - Uncontrolled hypertension, defined as systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg, despite optimal medical management. - Active clinically serious infection > CTCAE Grade 2. - Thromboembolic events such as a cerebrovascular accident (including transient ischemic attacks) within the past 6 months. - Any hemorrhage/bleeding event = CTCAE Grade 3 within 4 weeks of first dose of study drug. - Serious non-healing wound, ulcer, or bone fracture within 4 weeks of first dose of study drug. - Evidence or history of bleeding diathesis or coagulopathy within 4 weeks of first dose of study drug. - Major surgery, open biopsy or significant traumatic injury within 4 weeks of first study drug. - Use of St. John's Wort or rifampin within 4 weeks of first dose of study drug. - Known or suspected allergy to sorafenib or any agent given in the course of this trial. - Any condition that impairs patient's ability to swallow whole pills. - Patients who are pregnant or breastfeeding. Breastfeeding should be discontinued if the patient is to be treated. - Prior malignancy treated during the prior 5-years (other than localized non-melanoma carcinoma of the skin). - Any condition or social situation that may limit patient's compliance with the study regimen - Known brain metastasis. Patients with neurological symptoms must undergo a CT scan/MRI of the brain to exclude brain metastasis prior to enrollment. - Known human immunodeficiency virus (HIV) infection (hepatitis B and hepatitis C infection will not be exclusion criteria. - Pulmonary hemorrhage/bleeding event = CTCAE Grade 2 within 4 weeks of first dose of study drug. - Any malabsorption problem which in the investigator's opinion would prevent adequate absorption of the sorafenib. - On M-Tor inhibitors |
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | University of California, Los Angeles | Los Angeles | California |
United States | University of Southern California | Los Angeles | California |
United States | Columbia University Medical Center | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Columbia University | Bayer, Onyx Pharmaceuticals |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximum tolerated dose of daily sorafenib | Every two weeks throughout six cycles | Yes | |
Secondary | Duration of disease free survival | Every three months for 2 years | No | |
Secondary | Duration of progression free survival | Every three months for 2 years | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03971201 -
A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With Portal Vein Invasion
|
Phase 2 | |
Recruiting |
NCT05489250 -
The PLATON Network
|
||
Recruiting |
NCT04484636 -
PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)
|
N/A | |
Completed |
NCT01967823 -
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
|
Phase 2 | |
Terminated |
NCT00878215 -
Clinical Application of Image-Guided Liver Surgery
|
Phase 2 | |
Completed |
NCT04212286 -
Comparing the Diagnostic Efficiencies of CEUS and EOB-MRI in Patients With High Risk of HCC
|
N/A | |
Recruiting |
NCT05992220 -
Atezolizumab Plus Bevacizumab Alone or Combined With External Beam Radiotherapy for HCC With Macrovascular Invasion
|
Phase 2 | |
Completed |
NCT02073435 -
A2ALL-Patients Safety System Improvements in Living Donor Liver Transplantation
|
||
Active, not recruiting |
NCT01522937 -
A Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer
|
Phase 2 | |
Terminated |
NCT05061537 -
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT04166240 -
Measuring and Improving the Safety of Test Result Follow-Up
|
N/A | |
Withdrawn |
NCT02288507 -
Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer
|
Phase 1 | |
Terminated |
NCT03026803 -
A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04682847 -
Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers
|
||
Active, not recruiting |
NCT05100082 -
Survey of Cabozantinib Tablets Used To Treat People With Hepatocellular Carcinoma
|
||
Active, not recruiting |
NCT03195699 -
Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers
|
Phase 1 | |
Completed |
NCT02616692 -
HCC Patient Preferences in Japan
|
N/A | |
Active, not recruiting |
NCT03132792 -
AFPᶜ³³²T in Advanced HCC
|
Phase 1 | |
Recruiting |
NCT01849588 -
Sorafenib for Hepatocellular Cancer With Chronic Hepatitis C
|
Phase 4 | |
Suspended |
NCT00909558 -
Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer
|
Phase 1 |